IFM Investors Pty Ltd raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 110.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,879 shares of the biopharmaceutical company’s stock after buying an additional 18,846 shares during the period. IFM Investors Pty Ltd’s holdings in Gilead Sciences were worth $2,540,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Freestone Capital Holdings LLC lifted its holdings in shares of Gilead Sciences by 2.2% during the second quarter. Freestone Capital Holdings LLC now owns 282,543 shares of the biopharmaceutical company’s stock worth $19,998,000 after purchasing an additional 6,027 shares during the period. Bienville Capital Management LLC lifted its holdings in shares of Gilead Sciences by 18.3% during the second quarter. Bienville Capital Management LLC now owns 9,925 shares of the biopharmaceutical company’s stock worth $702,000 after purchasing an additional 1,535 shares during the period. Shoker Investment Counsel Inc. lifted its holdings in shares of Gilead Sciences by 7.3% during the second quarter. Shoker Investment Counsel Inc. now owns 4,340 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 294 shares during the period. Provident Investment Management Inc. lifted its holdings in shares of Gilead Sciences by 3.5% during the second quarter. Provident Investment Management Inc. now owns 376,731 shares of the biopharmaceutical company’s stock worth $26,665,000 after purchasing an additional 12,682 shares during the period. Finally, Dearborn Partners LLC lifted its holdings in shares of Gilead Sciences by 2.1% during the second quarter. Dearborn Partners LLC now owns 217,227 shares of the biopharmaceutical company’s stock worth $15,375,000 after purchasing an additional 4,485 shares during the period. Hedge funds and other institutional investors own 74.62% of the company’s stock.

In related news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock valued at $36,269,486 over the last quarter. Company insiders own 1.30% of the company’s stock.

WARNING: “Gilead Sciences, Inc. (GILD) Shares Bought by IFM Investors Pty Ltd” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-bought-by-ifm-investors-pty-ltd/1701571.html.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.85 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a market cap of $96,363.46, a P/E ratio of 7.70, a PEG ratio of -1.24 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period in the previous year, the business posted $2.75 earnings per share. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.86%. Gilead Sciences’s dividend payout ratio is presently 23.69%.

GILD has been the topic of a number of recent research reports. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Deutsche Bank AG reissued a “buy” rating and set a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research note on Monday, July 17th. Redburn Partners began coverage on shares of Gilead Sciences in a research note on Wednesday, July 26th. They set a “buy” rating for the company. Finally, BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $84.87.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.